FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3171679282> ?p ?o ?g. }

• W3171679282 abstract "Abstract Background and Aims Immunoglobulin A (IgA) nephropathy (IgAN) is a glomerulonephritis characterized by the presence of circulating and glomerular immune complexes containing galactose-deficient (Gd) IgA1. A proliferation-inducing ligand (APRIL), a member of the tumor necrosis factor superfamily of ligands, is thought to play a key role in the pathogenesis of IgAN by virtue of its role in class-switching to IgA production. VIS649, a humanized immunoglobulin G (IgG2) monoclonal antibody that binds to and blocks the biological actions of APRIL, is in clinical development as a potential treatment for IgAN. The primary objective of this first-in-human study was to evaluate the safety and tolerability of VIS649 in healthy volunteers. Secondary objectives included characterization of the pharmacokinetics (PK) and pharmacodynamics (PD) of VIS649. Method This was a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose study of VIS649 in healthy adult male and female volunteers (ClinicalTrials.gov identifier: NCT03719443). The study was conducted in sequential dosing cohorts. The first four cohorts (0.5, 2.0, 6.0, and 12.0 mg/kg, respectively) each enrolled 9 participants (4 of Japanese descent and 5 of non-Japanese descent) who were randomized to VIS649 or placebo in a ratio of 7:2. In addition, a fifth cohort enrolled 15 adults randomized to receive VIS649 6.0 mg/kg or placebo (10:5), followed by tetanus/diphtheria vaccine challenge after 28 days (TENIVAC®, Sanofi Pasteur Limited; the effect of APRIL inhibition on vaccine response is described in a companion abstract). Participants received intravenous administration of study drug on Day 1, were discharged from the institution on Day 2, and were followed for 16–24 weeks on an outpatient basis. Standard safety assessments and blood sampling for PK and PD were performed at regular intervals. Results 51 participants were randomized and dosed with study drug, of whom 47 (92.2%) completed the study. VIS649 was well tolerated, with no serious adverse events (AEs) or AEs that led to study discontinuation. Most treatment-emergent AEs (TEAEs) were mild; the incidence and severity of TEAEs were not dose dependent. One participant in the 2.0 mg/kg group experienced a severe TEAE of syncope following phlebotomy that the investigator considered unlikely to be related to study drug. There was no clinically relevant effect of treatment on laboratory tests, vital signs, electrocardiogram parameters, or physical examinations. VIS649 had non-linear PK: half-life (t½) increased with dose, while drug exposure (AUC) increased in a greater than dose proportional manner. Serum IgA, Gd-IgA1, IgG, and IgM were reversibly suppressed in a dose-dependent manner following VIS649 administration. The maximum mean percentage reductions from baseline occurred at Week 12 for the 12.0 mg/kg dose: IgA, -57.2% (Figure); Gd-IgA1, -71.6% (Figure); IgG, -33.6%; and IgM, -67.2%. These reductions were reversible and showed a dose-response effect with respect to time-to-recovery. Mean free (non-VIS649 bound) serum APRIL levels decreased to the lower limit of quantification (50 pg/mL) for all VIS649 doses at Week 1, and also showed a dose-response effect with respect to time-to-recovery. No depletions in circulating lymphocyte populations were observed. There were no significant PK or PD differences between Japanese and non-Japanese participants. Conclusion A single dose of VIS649, up to 12.0 mg/kg, was safe and well tolerated in healthy adults and was able to suppress free serum APRIL to the lower level of quantification. Serum Gd-IgA1 decreased in parallel with total serum IgA and recovered in a dose-dependent manner following reappearance of free APRIL in serum. These data support the further clinical development of VIS649 as a potential treatment for IgAN." @default.
• W3171679282 created "2021-06-22" @default.
• W3171679282 creator A5012937961 @default.
• W3171679282 creator A5048973524 @default.
• W3171679282 creator A5053336305 @default.
• W3171679282 creator A5055078486 @default.
• W3171679282 creator A5063282926 @default.
• W3171679282 creator A5076815130 @default.
• W3171679282 creator A5078883987 @default.
• W3171679282 date "2021-05-01" @default.
• W3171679282 modified "2023-10-01" @default.
• W3171679282 title "MO258SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF VIS649, AN APRIL-NEUTRALIZING IGG2 MONOCLONAL ANTIBODY, IN HEALTHY VOLUNTEERS: PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY" @default.
• W3171679282 doi "https://doi.org/10.1093/ndt/gfab104.0016" @default.
• W3171679282 hasPublicationYear "2021" @default.
• W3171679282 type Work @default.
• W3171679282 sameAs 3171679282 @default.
• W3171679282 citedByCount "4" @default.
• W3171679282 countsByYear W31716792822021 @default.
• W3171679282 countsByYear W31716792822022 @default.
• W3171679282 countsByYear W31716792822023 @default.
• W3171679282 crossrefType "journal-article" @default.
• W3171679282 hasAuthorship W3171679282A5012937961 @default.
• W3171679282 hasAuthorship W3171679282A5048973524 @default.
• W3171679282 hasAuthorship W3171679282A5053336305 @default.
• W3171679282 hasAuthorship W3171679282A5055078486 @default.
• W3171679282 hasAuthorship W3171679282A5063282926 @default.
• W3171679282 hasAuthorship W3171679282A5076815130 @default.
• W3171679282 hasAuthorship W3171679282A5078883987 @default.
• W3171679282 hasConcept C111113717 @default.
• W3171679282 hasConcept C112705442 @default.
• W3171679282 hasConcept C126322002 @default.
• W3171679282 hasConcept C142724271 @default.
• W3171679282 hasConcept C197934379 @default.
• W3171679282 hasConcept C203014093 @default.
• W3171679282 hasConcept C204787440 @default.
• W3171679282 hasConcept C27081682 @default.
• W3171679282 hasConcept C2778375690 @default.
• W3171679282 hasConcept C71924100 @default.
• W3171679282 hasConcept C90924648 @default.
• W3171679282 hasConcept C98274493 @default.
• W3171679282 hasConceptScore W3171679282C111113717 @default.
• W3171679282 hasConceptScore W3171679282C112705442 @default.
• W3171679282 hasConceptScore W3171679282C126322002 @default.
• W3171679282 hasConceptScore W3171679282C142724271 @default.
• W3171679282 hasConceptScore W3171679282C197934379 @default.
• W3171679282 hasConceptScore W3171679282C203014093 @default.
• W3171679282 hasConceptScore W3171679282C204787440 @default.
• W3171679282 hasConceptScore W3171679282C27081682 @default.
• W3171679282 hasConceptScore W3171679282C2778375690 @default.
• W3171679282 hasConceptScore W3171679282C71924100 @default.
• W3171679282 hasConceptScore W3171679282C90924648 @default.
• W3171679282 hasConceptScore W3171679282C98274493 @default.
• W3171679282 hasIssue "Supplement_1" @default.
• W3171679282 hasLocation W31716792821 @default.
• W3171679282 hasOpenAccess W3171679282 @default.
• W3171679282 hasPrimaryLocation W31716792821 @default.
• W3171679282 hasRelatedWork W1830687917 @default.
• W3171679282 hasRelatedWork W1934667138 @default.
• W3171679282 hasRelatedWork W1966047811 @default.
• W3171679282 hasRelatedWork W2003042623 @default.
• W3171679282 hasRelatedWork W202460821 @default.
• W3171679282 hasRelatedWork W2074207917 @default.
• W3171679282 hasRelatedWork W2090169689 @default.
• W3171679282 hasRelatedWork W2329478898 @default.
• W3171679282 hasRelatedWork W2765994429 @default.
• W3171679282 hasRelatedWork W4298086959 @default.
• W3171679282 hasVolume "36" @default.
• W3171679282 isParatext "false" @default.
• W3171679282 isRetracted "false" @default.
• W3171679282 magId "3171679282" @default.
• W3171679282 workType "article" @default.